[CAS NO. 1369761-01-2] Cerdulatinib (PRT062070) hydrochloride
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1369761-01-2]
Store
Catalog
SLK-S7634
Brand
Selleck
CAS
1369761-01-2
DESCRIPTION [1369761-01-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 482 |
| Molecular Formula | C20H28ClN7O3S |
| SMILES | O=C(C1=CN=C(NC2=CC=C(N3CCN(S(=O)(CC)=O)CC3)C=C2)N=C1NC4CC4)N.[H]Cl |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0747 mL | 10.3734 mL | 20.7469 mL |
| 5 mM | 0.4149 mL | 2.0747 mL | 4.1494 mL |
| 10 mM | 0.2075 mL | 1.0373 mL | 2.0747 mL |
| 50 mM | - | - | - |
Description
Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for and , respectively. Also inhibits 19 other tested kinases with less than 200 nM.
Targets
In vitro
In human whole blood from normal donors, Cerdulatinib affects BCR-mediated B-cell activation by dual inhibition of SYK and JAK. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent NHL cell lines.
In vivo
In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage. In addition, Cerdulatinib also blocks BCR-induced B-cell activation and splenomegaly in mice.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.